IL172013A - Hepatitis C-inhibiting compounds and pharmaceutical preparations containing them - Google Patents
Hepatitis C-inhibiting compounds and pharmaceutical preparations containing themInfo
- Publication number
- IL172013A IL172013A IL172013A IL17201305A IL172013A IL 172013 A IL172013 A IL 172013A IL 172013 A IL172013 A IL 172013A IL 17201305 A IL17201305 A IL 17201305A IL 172013 A IL172013 A IL 172013A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- cycloalkyl
- compound according
- substituted
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47270903P | 2003-05-21 | 2003-05-21 | |
PCT/CA2004/000750 WO2004103996A1 (en) | 2003-05-21 | 2004-05-19 | Hepatitis c inhibitor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IL172013A true IL172013A (en) | 2011-10-31 |
Family
ID=33476973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL172013A IL172013A (en) | 2003-05-21 | 2005-11-17 | Hepatitis C-inhibiting compounds and pharmaceutical preparations containing them |
Country Status (33)
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9712544B1 (pt) | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
CN1791599A (zh) | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
CA2536182C (en) * | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
KR20060130027A (ko) * | 2003-10-10 | 2006-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의억제제 |
US7132504B2 (en) * | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2358333T3 (es) * | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
AR048401A1 (es) | 2004-01-30 | 2006-04-26 | Medivir Ab | Inhibidores de la serina-proteasa ns3 del vhc |
EP1718608B1 (en) | 2004-02-20 | 2013-07-17 | Boehringer Ingelheim International GmbH | Viral polymerase inhibitors |
JP4654239B2 (ja) | 2004-03-15 | 2011-03-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法 |
EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
US7705146B2 (en) | 2004-06-28 | 2010-04-27 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
MX2007003812A (es) * | 2004-10-01 | 2007-05-24 | Vertex Pharma | Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc). |
MY141025A (en) | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2006096652A2 (en) * | 2005-03-08 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI449711B (zh) * | 2005-06-30 | 2014-08-21 | Virobay Inc | C型肝炎病毒(hcv)抑制劑 |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
AU2006275605B2 (en) | 2005-08-01 | 2011-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic peptides as HCV NS3 protease inhibitors |
NZ565540A (en) * | 2005-08-02 | 2011-06-30 | Vertex Pharma | Inhibitors of serine proteases |
JP5015154B2 (ja) | 2005-08-12 | 2012-08-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7884246B2 (en) * | 2005-11-03 | 2011-02-08 | Boehringer Ingelheim International Gmbh | Process for preparing substituted anisidines |
WO2007130704A1 (en) * | 2006-01-25 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A two step process for preparing substituted anisidines |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
JP5436864B2 (ja) | 2006-02-27 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vx−950を含む共結晶体およびそれを含む医薬組成物 |
EP1993994A2 (en) | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2008008502A1 (en) | 2006-07-13 | 2008-01-17 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
US7718612B2 (en) * | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
AU2007284027A1 (en) | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
JP2010507656A (ja) | 2006-10-24 | 2010-03-11 | メルク エンド カムパニー インコーポレーテッド | Hcvns3プロテアーゼ阻害剤 |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
ES2444575T3 (es) | 2006-10-27 | 2014-02-25 | Merck Sharp & Dohme Corp. | Inhibidores de la proteasa NS3 del VHC |
KR101615500B1 (ko) | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | Hcv ns3 프로테아제 억제제 |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008075103A1 (en) | 2006-12-20 | 2008-06-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
EP2495249A1 (en) | 2007-02-26 | 2012-09-05 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
SI2114924T1 (sl) * | 2007-02-27 | 2012-06-29 | Vertex Pharma | Ko-kristali in farmacevtski sestavki, ki jih vsebujejo |
NZ579295A (en) * | 2007-02-27 | 2012-03-30 | Vertex Pharma | Inhibitors of serine proteases |
AP2874A (en) | 2007-06-29 | 2014-03-31 | Gilead Sciences Inc | Antiviral compounds |
CA2692145C (en) | 2007-06-29 | 2015-03-03 | Gilead Sciences, Inc. | Antiviral compounds |
CA2693533A1 (en) | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
WO2009010804A1 (en) | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
CN101835774B (zh) * | 2007-08-30 | 2014-09-17 | 弗特克斯药品有限公司 | 共晶体和包含该共晶体的药物组合物 |
JP2010540549A (ja) | 2007-09-24 | 2010-12-24 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ウイルス複製阻害剤としての尿素含有ペプチド |
MX2010006209A (es) * | 2007-12-05 | 2010-08-10 | Enanta Pharm Inc | Derivados de quinoxalinilo. |
JP5529036B2 (ja) | 2007-12-05 | 2014-06-25 | エナンタ ファーマシューティカルズ インコーポレイテッド | フッ素化トリペプチドhcvセリンプロテアーゼ阻害剤 |
CN101903351B (zh) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
TWI487522B (zh) | 2007-12-21 | 2015-06-11 | 賽基艾維洛米斯研究股份有限公司 | Hcv蛋白酶抑制劑及其用途(一) |
JP5755449B2 (ja) * | 2007-12-21 | 2015-07-29 | セルジーン アビロミクス リサーチ, インコーポレイテッド | Hcvプロテアーゼ阻害剤およびその使用 |
US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
ES2437147T3 (es) * | 2008-02-04 | 2014-01-09 | Idenix Pharmaceuticals, Inc. | Inhibidores de serina proteasa macrocíclicos |
JP5608563B2 (ja) * | 2008-02-25 | 2014-10-15 | メルク・シャープ・アンド・ドーム・コーポレーション | 治療用化合物 |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2009241445A1 (en) | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
RS53420B (en) | 2008-07-22 | 2014-12-31 | Msd Italia S.R.L. | MACROCYCLIC COMPOUNDS OF HINOXALINE, WHICH IS AN INHIBITOR OF HCV NS3 PROTEASES WITH OTHER HCV AGENTS |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
AU2014201788B2 (en) * | 2008-09-16 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
ME01831B (me) * | 2008-09-16 | 2014-12-20 | Boehringer Ingelheim Int | Kristalni oblici 2-tiazolil-4-hinolinil-oksi derivata, snažni hcv inhibitor |
KR20110054003A (ko) * | 2008-09-17 | 2011-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | Hcv ns3 프로테아제 억제제와 인터페론 및 리바비린의 병용물 |
EP2344487A4 (en) * | 2008-09-23 | 2012-03-21 | Boehringer Ingelheim Int | HEPATITIS C INHIBITOR COMPOUNDS |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2445516T3 (es) * | 2008-11-21 | 2014-03-03 | Boehringer Ingelheim International Gmbh | Composición farmacéutica de un potente inhibidor de HCV para su administración oral |
PT2364309E (pt) | 2008-12-10 | 2015-01-14 | Achillion Pharmaceuticals Inc | Novos péptidos 4-amino-4-oxobutanoil como inibidores de replicação viral |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102300871A (zh) | 2008-12-19 | 2011-12-28 | 吉里德科学公司 | Hcv ns3蛋白酶抑制剂 |
EP2385838A1 (en) | 2009-01-07 | 2011-11-16 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
JP2012517478A (ja) | 2009-02-12 | 2012-08-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、hcv組合せ治療剤 |
JP2012520891A (ja) | 2009-03-19 | 2012-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホニルキノリンの製造方法 |
JP5642766B2 (ja) * | 2009-03-26 | 2014-12-17 | ダエウン ファーマシューティカル カンパニー リミテッド | アデフォビルジピボキシルの新規結晶形及びその製造方法 |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
WO2010129451A1 (en) | 2009-05-05 | 2010-11-11 | Boehringer Ingelheim International Gmbh | Process for preparing bromo-substituted quinolines |
US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
MX2011013824A (es) * | 2009-07-07 | 2012-01-30 | Boehringer Ingelheim Int | Composicion farmaceutica para un inhibidor de proteasa del virus de la hepatitis c. |
WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
US8324417B2 (en) | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
KR20120106942A (ko) | 2009-10-30 | 2012-09-27 | 베링거 인겔하임 인터내셔날 게엠베하 | Bi201335, 인터페론 알파 및 리바비린을 포함하는 hcv 병용 치료요법을 위한 투여 용법 |
AU2010333656B2 (en) * | 2009-12-18 | 2015-08-27 | Boehringer Ingelheim International Gmbh | HCV combination therapy |
CN102844030A (zh) | 2010-01-29 | 2012-12-26 | 沃泰克斯药物股份有限公司 | 用于治疗丙型肝炎病毒感染的疗法 |
US8530497B2 (en) * | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
US20120014912A1 (en) | 2010-07-14 | 2012-01-19 | Vertex Pharmaceuticals Incorporated | Palatable pharmaceutical composition |
HUE028384T2 (en) | 2010-09-21 | 2016-12-28 | Enanta Pharm Inc | HCV serine protease inhibitors derived from macrocyclic proline |
BR112013007423A2 (pt) | 2010-09-30 | 2016-07-12 | Boehringer Ingelheim Int | terapia combinada no que diz respeito ao tratamento da infecção por hcv |
AU2011311880B2 (en) * | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
US10873190B2 (en) | 2010-11-19 | 2020-12-22 | Tseng-Lu Chien | Desktop or floor LED lighting device has USB-port(s) |
US10873191B2 (en) | 2010-11-19 | 2020-12-22 | Tseng-Lu Chien | Desk top alarm or time or LED lighting device has USB-port(s) |
EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
WO2012109646A1 (en) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Treatment of hcv in hiv infection patients |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2012176149A1 (en) | 2011-06-23 | 2012-12-27 | Panmed Ltd. | Treatment of hepatitis c virus |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8853176B2 (en) | 2011-10-21 | 2014-10-07 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
CA2861041A1 (en) | 2012-01-12 | 2013-07-18 | Boehringer Ingelheim International Gmbh | Stabilized pharmaceutical formulations of a potent hcv inhibitor |
WO2013116339A1 (en) | 2012-01-31 | 2013-08-08 | Vertex Pharmaceuticals Incorporated | High potency formulations of vx-950 |
WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
JP5870001B2 (ja) | 2012-09-28 | 2016-02-24 | 株式会社吉野工業所 | ブロー成形装置及び容器の製造方法 |
PT2909205T (pt) | 2012-10-19 | 2017-02-06 | Bristol Myers Squibb Co | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
CA2905433A1 (en) | 2013-03-14 | 2014-09-25 | Achillion Pharmaceuticals, Inc. | Novel processes for producing sovaprevir |
US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
MX2015013020A (es) | 2013-03-15 | 2016-06-10 | Achillion Pharmaceuticals Inc | Polimorfos de sovaprevir y metodos de fabricacion de los mismos. |
CA2902569A1 (en) | 2013-03-15 | 2014-09-18 | Gilead Sciences, Inc. | Inhibitors of hepatitis c virus |
WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
UA116237C2 (uk) * | 2013-03-15 | 2018-02-26 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Тверда пероральна дозована композиція інгібітору нсv в аморфному стані |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
KR20170016975A (ko) * | 2014-06-12 | 2017-02-14 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 헤테로환형 화합물 및 이의 사용 방법 |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
CN108610301B (zh) * | 2016-12-12 | 2021-08-31 | 中山大学 | 一类手性芳杂胺类衍生物及其合成方法和应用 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US684806A (en) * | 1900-03-08 | 1901-10-22 | Filter & Brautechnische Maschinen Fabrik Akt Ges Vorm L A Enzinger | Pressure-regulator for pumps. |
AR205953A1 (es) * | 1975-01-22 | 1976-06-15 | Diamond Shamrock Corp | Produccion de carbonatos de metales a calinos en una celula de membrana |
DE3481913D1 (de) | 1983-04-27 | 1990-05-17 | Ici America Inc | Prolin-derivate. |
JPH01103993A (ja) | 1987-10-16 | 1989-04-21 | Sumitomo Electric Ind Ltd | ダイヤモンド単結晶成長方法 |
JPH01135478A (ja) | 1987-11-19 | 1989-05-29 | Brother Ind Ltd | 研削工具 |
US5164402A (en) | 1989-08-16 | 1992-11-17 | Pfizer Inc | Azabicyclo quinolone and naphthyridinone carboxylic acids |
US5290405A (en) * | 1991-05-24 | 1994-03-01 | Ceramatec, Inc. | NaOH production from ceramic electrolytic cell |
JPH05155827A (ja) | 1991-12-09 | 1993-06-22 | Banyu Pharmaceut Co Ltd | cis−2−アミノシクロプロパンカルボン酸誘導体の製造法 |
DK0804465T3 (da) | 1994-06-02 | 2003-11-24 | Aventis Pharma Inc | Nye elastaseinhibitorer |
DE4430601A1 (de) | 1994-08-22 | 1996-02-29 | Beiersdorf Ag | Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander |
US6159938A (en) | 1994-11-21 | 2000-12-12 | Cortech, Inc. | Serine protease inhibitors comprising α-keto heterocycles |
DE4444893A1 (de) | 1994-12-16 | 1996-06-20 | Merck Patent Gmbh | Peptide und synthetische Zellmembranen |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
DE19600034C2 (de) | 1996-01-02 | 2003-12-24 | Degussa | 1,1,2-Trisubstituierte Cyclopropanverbindungen, Verfahren zu deren Herstellung und Dihydroxyethyl-substituierte 1-Amino-cyclopropan-1-carbonsäure |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
CA2254122A1 (en) | 1996-05-10 | 1997-11-20 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
BR9712544B1 (pt) | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
AU7127298A (en) | 1997-04-14 | 1998-11-11 | Emory University | Serine protease inhibitors |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
JPH10298151A (ja) | 1997-04-30 | 1998-11-10 | Japan Energy Corp | C型肝炎ウイルスプロテアーゼ阻害剤 |
JP2002512625A (ja) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
JPH1135478A (ja) | 1997-07-17 | 1999-02-09 | Soyaku Gijutsu Kenkyusho:Kk | キク科植物の有機抽出物を含有する抗c型肝炎ウイルス剤及びプロテアーゼns3の特異的阻害剤 |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
AU757783B2 (en) | 1997-08-11 | 2003-03-06 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
JPH11127861A (ja) | 1997-10-29 | 1999-05-18 | Japan Energy Corp | C型肝炎ウイルス由来のセリンプロテアーゼに対する中和抗体部分ペプチド |
JP3612551B2 (ja) | 1997-11-07 | 2005-01-19 | 独立行政法人産業技術総合研究所 | C型肝炎ウイルスのns3プロテアーゼを阻害するrna分子 |
SE9704543D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
WO1999050230A1 (en) | 1998-03-31 | 1999-10-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
JPH11292840A (ja) | 1998-04-06 | 1999-10-26 | Soyaku Gijutsu Kenkyusho:Kk | ノルスタチン誘導体又はその塩 |
US6455571B1 (en) | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
GB9809664D0 (en) | 1998-05-06 | 1998-07-01 | Hoffmann La Roche | a-Ketoamide derivatives |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
AU1099000A (en) | 1998-10-05 | 2000-04-26 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
CA2376965A1 (en) | 1999-07-07 | 2001-01-11 | Timothy Patrick Forsyth | Peptide boronic acid inhibitors of hepatitis c virus protease |
AU6371900A (en) | 1999-07-26 | 2001-02-13 | Du Pont Pharmaceuticals Company | Lactam inhibitors of hepatitis c virus ns3 protease |
WO2001016357A2 (en) | 1999-08-30 | 2001-03-08 | K.U. Leuven Research & Development | Novel target for antiparasitic agents and inhibitors thereof |
JP2001103993A (ja) | 1999-10-05 | 2001-04-17 | Japan Energy Corp | 環状ペプチド及びセリンプロテアーゼ阻害剤 |
US6222241B1 (en) * | 1999-10-29 | 2001-04-24 | Advanced Micro Devices, Inc. | Method and system for reducing ARC layer removal by providing a capping layer for the ARC layer |
GB9925955D0 (en) | 1999-11-02 | 1999-12-29 | Angeletti P Ist Richerche Bio | Hcv n33 protease inhibitors |
US6774212B2 (en) | 1999-12-03 | 2004-08-10 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
AU2001234837A1 (en) | 2000-02-08 | 2001-08-20 | Schering Corporation | Azapeptides useful in the treatment of hepatitis c |
WO2001064678A2 (en) | 2000-02-29 | 2001-09-07 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
IL152022A0 (en) | 2000-04-03 | 2003-04-10 | Vertex Pharma | Compounds useful as protease inhibitors and pharmaceutical compositions containing the same |
EP1268525B1 (en) | 2000-04-05 | 2008-12-31 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
AR030558A1 (es) | 2000-04-19 | 2003-08-27 | Schering Corp | COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA, |
AU2001276988B2 (en) | 2000-07-21 | 2007-01-25 | Dendreon Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
EP1301527A2 (en) | 2000-07-21 | 2003-04-16 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
RU2003105221A (ru) | 2000-07-21 | 2004-09-20 | Шеринг Корпорейшн (US) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
BR0115447A (pt) | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Inibidores de tripeptìdeo de hepatite c |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CA2474156C (en) | 2002-02-01 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c) |
AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ATE503764T1 (de) | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
ATE481106T1 (de) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
CA2516016C (en) | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
CN1791599A (zh) * | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
CA2536182C (en) | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP5314246B2 (ja) * | 2003-12-11 | 2013-10-16 | アメリカン パシフィック コーポレイション | イオン伝導性セラミックの固体膜を用いたアルカリアルコラートを生成するための電気分解による方法 |
AR048401A1 (es) * | 2004-01-30 | 2006-04-26 | Medivir Ab | Inhibidores de la serina-proteasa ns3 del vhc |
EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
RU2004119195A (ru) | 2004-06-24 | 2005-12-10 | Дмитрий Александрович Гертнер (RU) | Способ бесконтактной, гарантированной доставки товаров до конечного потребителя и система для его реализации |
US7705146B2 (en) | 2004-06-28 | 2010-04-27 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
WO2008124047A1 (en) * | 2007-04-03 | 2008-10-16 | Ceramatec, Inc. | Electrochemical process to recycle aqueous alkali chemicals using ceramic ion conducting solid membranes |
US20090090638A1 (en) * | 2007-10-05 | 2009-04-09 | Kelly Michael T | Processes and reactors for alkali metal production |
US8246863B2 (en) * | 2009-06-26 | 2012-08-21 | Ceramatec, Inc. | Alkali metal super ionic conducting ceramic |
-
2004
- 2004-05-19 CN CNA2004800137831A patent/CN1791599A/zh active Pending
- 2004-05-19 PE PE2004000512A patent/PE20050204A1/es active IP Right Grant
- 2004-05-19 EA EA200501689A patent/EA009295B1/ru not_active IP Right Cessation
- 2004-05-19 PL PL04733750T patent/PL1654261T3/pl unknown
- 2004-05-19 MY MYPI20041902A patent/MY143076A/en unknown
- 2004-05-19 ES ES04733750T patent/ES2297424T3/es active Active
- 2004-05-19 AU AU2004240704A patent/AU2004240704B9/en not_active Ceased
- 2004-05-19 DE DE602004010137T patent/DE602004010137T2/de active Active
- 2004-05-19 ME MEP-583/08A patent/MEP58308A/xx unknown
- 2004-05-19 JP JP2006529495A patent/JP4447603B2/ja not_active Expired - Fee Related
- 2004-05-19 DK DK04733750T patent/DK1654261T3/da active
- 2004-05-19 UA UAA200512307A patent/UA83046C2/ru unknown
- 2004-05-19 CL CL200401161A patent/CL2004001161A1/es unknown
- 2004-05-19 WO PCT/CA2004/000750 patent/WO2004103996A1/en active IP Right Grant
- 2004-05-19 EP EP04733750A patent/EP1654261B1/en active Active
- 2004-05-19 CN CN201310097223XA patent/CN103203010A/zh active Pending
- 2004-05-19 PT PT04733750T patent/PT1654261E/pt unknown
- 2004-05-19 MX MXPA05012545A patent/MXPA05012545A/es active IP Right Grant
- 2004-05-19 AT AT04733750T patent/ATE378334T1/de active
- 2004-05-19 KR KR1020057022088A patent/KR101115294B1/ko active IP Right Grant
- 2004-05-19 CN CN2013100935669A patent/CN103204903A/zh active Pending
- 2004-05-19 BR BRPI0410456A patent/BRPI0410456B8/pt not_active IP Right Cessation
- 2004-05-19 UY UY28323A patent/UY28323A1/es not_active Application Discontinuation
- 2004-05-19 CA CA2522577A patent/CA2522577C/en not_active Expired - Fee Related
- 2004-05-19 RS YUP-2005/0871A patent/RS51294B/sr unknown
- 2004-05-19 NZ NZ544076A patent/NZ544076A/en not_active IP Right Cessation
- 2004-05-20 TW TW093114272A patent/TWI327145B/zh not_active IP Right Cessation
- 2004-05-20 US US10/850,101 patent/US7585845B2/en active Active
-
2005
- 2005-10-11 ZA ZA200508201A patent/ZA200508201B/en unknown
- 2005-11-17 IL IL172013A patent/IL172013A/en active IP Right Grant
- 2005-11-18 CO CO05117348A patent/CO5630024A2/es active IP Right Grant
- 2005-11-21 EC EC2005006181A patent/ECSP056181A/es unknown
- 2005-12-19 NO NO20056047A patent/NO332056B1/no not_active IP Right Cessation
-
2007
- 2007-06-21 US US11/766,171 patent/US7939667B2/en active Active
-
2008
- 2008-01-11 HR HR20080014T patent/HRP20080014T3/xx unknown
- 2008-02-14 CY CY20081100184T patent/CY1107200T1/el unknown
-
2009
- 2009-11-24 JP JP2009266291A patent/JP2010043129A/ja not_active Withdrawn
-
2011
- 2011-04-01 US US13/078,225 patent/US8067438B2/en active Active
- 2011-10-21 US US13/278,532 patent/US20120034187A1/en not_active Abandoned
-
2012
- 2012-07-03 US US13/540,859 patent/US20120269769A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8067438B2 (en) | Hepatitis C inhibitor compounds | |
US7642235B2 (en) | Macrocyclic peptides active against the hepatitis C virus | |
US7091184B2 (en) | Hepatitis C inhibitor tri-peptides | |
US6919423B2 (en) | Hepatitis C inhibitor compound | |
EP1474423B1 (en) | Heterocyclic tripeptides as hepatitis c inhibitors | |
US20040224900A1 (en) | Hepatitis C inhibitor peptide analogs | |
US20030187018A1 (en) | Hepatitis C inhibitor tri-peptides | |
AU2003202348A1 (en) | Heterocyclic tripeptides as hepatitis c inhibitors | |
CA2474156C (en) | Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c) | |
CA2474031C (en) | Heterocyclic tripeptides as hepatitis c inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed |